乌帕替尼治疗巨细胞动脉炎两年延续与撤药的临床结局
SELECT-GCA 试验第二期再随机分析显示,在获得至少24周持续缓解的巨细胞动脉炎患者中,继续使用乌帕替尼15mg/d相比换用安慰剂,52至104周疾病复发更少、无糖皮质激素缓解维持率更高、激素暴露更低,安全性总体相似。
要点
- 持续缓解的GCA患者继续乌帕替尼15mg较撤药显著降低复发并维持无激素缓解。
- 乌帕替尼15mg延续治疗两年未发现新的临床显著安全风险。
- 数据支持乌帕替尼15mg延长用于GCA治疗具有有利的风险获益特征。
核心结论
- 在获得至少24周持续缓解的GCA患者中,继续乌帕替尼15mg治疗至2年较撤药可显著减少疾病复发并维持无糖皮质激素缓解。
研究设计与样本
- SELECT-GCA为随机、双盲、安慰剂对照试验,第二期将第52周前达到至少24周连续缓解的患者按2:1再随机分配继续乌帕替尼或换用安慰剂。
- 第二期共纳入103例接受乌帕替尼15mg且达到至少24周持续缓解并再随机的患者,68例继续治疗、35例换用安慰剂。
主要发现
- 第52至104周,继续乌帕替尼15mg组相比换用安慰剂组疾病复发率更低(7.4% vs 59.5%;P ≤ .0001)。
- 继续乌帕替尼15mg组无糖皮质激素缓解维持率更高(71.7% vs 31.4%;P ≤ .0001)。
- 继续乌帕替尼15mg组糖皮质激素暴露中位数更低(0 mg vs 1048 mg;P ≤ .0001)。
- 乌帕替尼与安慰剂组安全性总体相似,两年内未发现新的临床显著安全风险。
关键数值与推荐
- 第二期再随机条件为第52周前达到至少24周连续缓解。
- 所有P值均为名义P值。
临床怎么用
- 对已获得持续缓解的GCA患者,继续乌帕替尼15mg可能有助于维持缓解并减少激素暴露。
局限性
- 所有P值均为名义P值,未进行多重比较校正。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In the SELECT-GCA trial, upadacitinib 15 mg/d was associated with higher rates of disease remission and reduced glucocorticoid exposure vs placebo in patients with giant cell arteritis (GCA) through 1 year. This study evaluated the clinical impact of upadacitinib continuation vs withdrawal through 2 years. METHODS: In period 1 of SELECT-GCA, patients aged ≥50 years were randomised 2:1:1 to oral upadacitinib 15 mg or 7.5 mg with a 26-week glucocorticoid taper or placebo with a 52-week taper. In period 2 (52-week re-randomised, blinded extension), patients achieving ≥24 weeks of consecutive remission by week 52 were re-randomised 2:1 to continue upadacitinib or switch to placebo. Efficacy endpoints were assessed from weeks 52 to 104, and safety was evaluated over 2 years. All P values are nominal. RESULTS: Among 103 patients receiving upadacitinib 15 mg who achieved ≥24 weeks sustained remission and were re-randomised in period 2, 68 continued treatment and 35 switched to placebo at week 52. From weeks 52 to 104, patients continuing upadacitinib 15 mg vs switching to placebo experienced fewer disease flares (7.4% vs 59.5%; P ≤ .0001), greater maintenance of glucocorticoid-free remission (71.7% vs 31.4%; P ≤ .0001), and lower glucocorticoid exposure (median exposure: 0 mg vs 1048 mg; P ≤ .0001). Safety was generally similar between upadacitinib and placebo groups. No new clinically significant safety risks were identified with upadacitinib through 2 years, and safety remained consistent with the established profile. CONCLUSIONS: These data further support a favourable benefit-risk profile for extended use of upadacitinib 15 mg for treatment of GCA.
引用
- Schmidt WA, Setty AR, Dejaco C, et al. Clinical outcomes of upadacitinib continuation vs withdrawal in giant cell arteritis through 2 years. Ann Rheum Dis. 2026. PMID: 42521523. doi:10.1016/j.ard.2026.06.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。